Association of tumour mutational burden (TMB) with outcomes in stage IIIA(N2) non-small cell lung cancer (NSCLC) patients treated with neoadjuvant chemotherapy and durvalumab: prospective analysis of the multicenter single-arm phase II trial SAKK16/14

被引：0
|
作者：
Alborelli, I [1 ]
Jermann, P. M. [2 ]
Leonards, K. [2 ]
Manzo, M. [2 ]
Keller, E. [2 ]
Zippelius, A. [1 ,3 ]
Eboulet, E., I [4 ]
Betticher, D. [5 ]
Frueh, M. [6 ]
Britschgi, C. [7 ]
Peters, S. [8 ]
Mark, M. [9 ]
Ochsenbein, A. F. [10 ]
Janthur, W. -D [11 ]
Waibel, C. [12 ]
Mach, N. [13 ]
Froesch, P. [14 ]
Pless, M. [15 ]
Prince, Savic S. [2 ]
Rothschild, S. [1 ]
机构：
[1] Univ Spital Basel, Med Onkol, Basel, Switzerland
[2] Univ Spital Basel, Inst Pathol, Basel, Switzerland
[3] Univ Spital Basel, Dept Biomed Lab Tumorimmunol, Basel, Switzerland
[4] Schweizer Arbeitsgemeinschaft Klin Krebsforsch SA, Bern, Switzerland
[5] HFR Fribourg Hop Fribourgeois, Med Onkol, Fribourg, Switzerland
[6] Kantonsspital St Gallen, Onkol Hamatol, St Gallen, Switzerland
[7] Univ Spital Zurich, Med Onkol & Hamatol, Zurich, Switzerland
[8] Ctr Hosp Univ Vaudois CHUV, Med Onkol, Lausanne, Switzerland
[9] Kantonsspital Graubunden, Onkol Hamatol, Chur, Switzerland
[10] Inselspital Bern, Med Onkol, Bern, Switzerland
[11] Kantonsspital Aarau, Onkol Hamatol & Transfus Med, Aarau, Switzerland
[12] Kantonsspital Baden, Onkol Hamatol, Baden, Switzerland
[13] Hop Univ Geneve, Med Onkol, Geneva, Switzerland
[14] Ist Oncol Svizzera Italiana IOSI, Bellinzona, Switzerland
[15] Kantonsspital Winterthur, Med Onkol, Winterthur, Switzerland
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ep658
引用
收藏
页码：174 / 175
页数：2
相关论文
共 50 条
  • [21] Neoadjuvant Camrelizumab Combined with Chemotherapy for Resectable Stage IIIA-IIIB Non-Small Cell Lung Cancer: Single Arm Phase II Study
    Cai, G.
    Wang, K.
    Wang, X.
    Zhao, J.
    Wang, Z.
    Han, X.
    Zhou, H.
    Xie, C.
    Fu, S.
    Hui, J.
    Huang, Y.
    Li, W.
    Teng, F.
    Wang, S.
    Yu, J.
    Song, P.
    Meng, X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E10 - E10
  • [22] Neoadjuvant camrelizumab combined with chemotherapy for resectable stage IIIA-IIIb non-small cell lung cancer: Single arm phase II study
    Cai, Guoxin
    Wang, Kaiyue
    Wang, Xiaohan
    Zhao, Jiarui
    Han, Xiao
    Zhou, Haiyan
    Xie, Chao
    Jia, Hui
    Fu, Shuai
    Huang, Yong
    Li, Wanhu
    Teng, Feifei
    Wang, Suzhen
    Yu, Jinming
    Song, Pingping
    Meng, Xue
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Durvalumab Combined with Concurrent Chemoradiotherapy in Patients with Limited-Stage Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Clinical Trial
    Shen, W. B.
    Song, C.
    Wang, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : S60 - S61
  • [24] Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial
    Bian, Dongliang
    Ji, Shuyu
    Liu, Yue
    Huang, Zhida
    Jiang, Lei
    Liu, Ming
    Bao, Xiao
    Yang, Jie
    Zhou, Yirui
    Hu, Junjie
    Sun, Liangdong
    Zheng, Yingzhi
    Huang, Jie
    Liu, Jing
    Zhu, Xinsheng
    Zhang, Jing
    Zhang, Lele
    Liu, Xiaogang
    He, Wenxin
    Xie, Dong
    Zhu, Yuming
    Wu, Chunyan
    Zhao, Deping
    Duan, Liang
    Jiang, Gening
    Zhang, Peng
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [25] First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
    Mark, Michael
    Froesch, Patrizia
    Gysel, Katrin
    Rothschild, Sacha I.
    Addeo, Alfredo
    Ackermann, Christoph J.
    Chiquet, Sabrina
    Schneider, Martina
    Ribi, Karin
    Maranta, Angela Fischer
    Bastian, Sara
    von Moos, Roger
    Joerger, Markus
    Frueh, Martin
    EUROPEAN JOURNAL OF CANCER, 2024, 200
  • [26] Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
    Song, Zhengbo
    Lv, Dongqing
    Chen, Shi-Qing
    Huang, Jianjin
    Li, Yuping
    Ying, Shenpeng
    Wu, Xiaoyu
    Hua, Feng
    Wang, Wenxian
    Xu, Chunwei
    Bei, Ting
    Gao, Chan
    Sun, Zhijian
    Zhang, Yiping
    Lu, Shun
    CLINICAL CANCER RESEARCH, 2022, 28 (03) : 461 - 467
  • [27] Anlotinib combination with docetaxol for patients with previously treated advanced non-small cell lung cancer: A phase II, single-arm trial
    Chen, X.
    Shen, J.
    Li, X.
    Yang, S.
    Xia, B.
    Wang, B.
    Wang, J.
    Zheng, S.
    Zhao, P.
    Ma, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S877 - S877
  • [28] Neoadjuvant camrelizumab, nab-paclitaxel, and carboplatin in patients with stage IB-IIIA non-small cell lung cancer (NANE-LC): a study protocol of prospective, single-arm, multicenter, phase II study
    Zhou, Haiyu
    Lin, Lili
    Qin, Tao
    Ren, Wei
    Tan, Yujie
    Yang, Qiong
    Xu, Huixin
    Xie, Xinxin
    Chen, Yongjian
    Liu, Shengbo
    Li, Xing
    Li, Zhihua
    Hu, Hai
    Yu, Yunfang
    Yao, Herui
    JOURNAL OF THORACIC DISEASE, 2021, 13 (11) : 6468 - 6475
  • [29] Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study
    Chen, Zhiwei
    Shen, Shengping
    Shi, Wenbo
    Jiang, Gening
    Wang, Xin
    Jian, Hong
    Zhou, Zhen
    Ding, Zhengping
    Lu, Shun
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 6543 - 6552
  • [30] A Phase II Trial of Individual Trimodality Treatment in Patients with Stage IIIA (N2) Non-Small Cell Lung Cancer: The ZTOG 1202 Study
    Xu, Yaping
    Chen, Qixun
    Yu, Xinmin
    Liu, Jinshi
    Zhao, Qiang
    Jiang, Youhua
    Zhou, Xinming
    Mao, Weimin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S570 - S571
12345